Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2006
08/31/2006WO2006090072A1 Ppar activator derivatives, preparation method thereof and use of same in therapeutics
08/31/2006WO2006090067A1 Solid pharmaceutical composition comprising telithromycin
08/31/2006WO2006090052A1 Novel 3-aryl-1,2-benzisoxazole derivatives, compositions containing same and use thereof
08/31/2006WO2006090047A1 Use of a pyrazole derivative for preparing medicines useful for preventing or treating renal diseases
08/31/2006WO2006090029A1 Gemcitabine derivatives nanoparticles
08/31/2006WO2006089973A2 Dosage form containing oxycodone and naloxone
08/31/2006WO2006089942A1 Protease inhibitor precursor synthesis
08/31/2006WO2006089909A1 Novel antithrombotic substituted pyrrolidinones, the production and use thereof in the form of medicaments
08/31/2006WO2006089881A1 Use of phenanthrene derivatives as anti-inflammatory agents, synthesis method and intermediate products
08/31/2006WO2006089874A1 Benzo[2,3]azepino[4,5-b]indol-6-ones
08/31/2006WO2006089872A1 Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
08/31/2006WO2006089871A2 Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
08/31/2006WO2006089861A2 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
08/31/2006WO2006089859A1 Novel drugs for treating respiratory diseases
08/31/2006WO2006089815A1 Novel pyrrolodihydroisoquinolines as pde10 inhibitors
08/31/2006WO2006089804A1 Aqueous topical gel of high stability based on metronidazole and method of preparation
08/31/2006WO2006089803A1 Method and composition to inhibit infections with helicobacter pylori by intake of procyanidins from type b and c
08/31/2006WO2006089798A1 2-sulfinyl- and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors
08/31/2006WO2006089787A1 Amorphous lercanidipine hydrochloride
08/31/2006WO2006089781A1 Pharmaceutical combination of bcr-abl and raf inhibitors
08/31/2006WO2006089746A1 Purification process
08/31/2006WO2006089708A1 Crystalline forms of (1rs,3rs,6rs)-6-dimethvlaminomethvl-1-(3-methoxv- phenyl)cyclohexane-1 ,3-diol hydrochloride
08/31/2006WO2006089707A1 Phosphate salts of 6-dimethylaminomethyl-l-(3-methoxyphenyl) -1,3-dihydroxycyclohexane compounds
08/31/2006WO2006089700A1 Pyrrolidine and piperidine acetylene derivatives for use as mglur5 antagonists
08/31/2006WO2006089689A1 2-quinolone compounds as inhibitors of phosphodiesterases
08/31/2006WO2006089664A2 Heterocyclylamide-substituted imidazoles
08/31/2006WO2006089658A2 Nk1 antagonists
08/31/2006WO2006089656A2 Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
08/31/2006WO2006089561A1 Pharmaceutical compositions containing organic acids useful for softening and ripening uterine cervix.
08/31/2006WO2006089546A1 Tablets comprising a high load of strontium
08/31/2006WO2006089494A1 Osmotic device containing amantadine and an osmotic salt
08/31/2006WO2006089478A1 The use of isoscutellarin for the manufacture of medicine
08/31/2006WO2006089406A1 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
08/31/2006WO2006089397A1 Methods for treating arthritis using triheterocyclic compounds
08/31/2006WO2006089348A1 Anti-microbial agent
08/31/2006WO2006089317A1 Pharmaceutical dosage form effective at microcirculatory level containing at least one flavonoid
08/31/2006WO2006078824A3 Eggshell membrane separation method
08/31/2006WO2006078287A9 Pde4b inhibitors and uses therefor
08/31/2006WO2006074940A3 Macrocyclic compounds and compositions useful as bace inhibitors
08/31/2006WO2006074914A3 Human rna helicase and therapeutic uses thereof
08/31/2006WO2006074388A3 TRICYCLIC δ-OPIOID MODULATORS
08/31/2006WO2006074223A3 Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
08/31/2006WO2006073572A3 Treatment of conditions caused by calcium abnormalities
08/31/2006WO2006072599A3 Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
08/31/2006WO2006072393A3 Sulfonyl pyrrolidines, method for producing the same and their use as drugs
08/31/2006WO2006070288A3 Aerosol generator
08/31/2006WO2006069242A3 Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders
08/31/2006WO2006066957A3 Sulfonamido-macrocycles as tie2 inhibitors
08/31/2006WO2006066924A3 Azole derivatives with antimuscarinic activity
08/31/2006WO2006066896A3 Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin
08/31/2006WO2006065711A3 Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists
08/31/2006WO2006065555A3 Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
08/31/2006WO2006062984A3 Inhibitors of protein kinases
08/31/2006WO2006061155A3 Stabilisation of glucocorticoid esters with acids
08/31/2006WO2006060614A9 Methods for preparing pimecrolimus
08/31/2006WO2006059194A3 Pharmaceutical sustained-release composition containing clozapine
08/31/2006WO2006057769A3 Method of delivering nasal spray
08/31/2006WO2006056696A3 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
08/31/2006WO2006056399A3 Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
08/31/2006WO2006050965A8 Pyrimidine compounds as histamine modulators
08/31/2006WO2006048747A8 Topical pharmaceutical compositions containing an antiacne compound and antibiotic compound
08/31/2006WO2006044933B1 Compositions and methods for disruption of brca2-rad51 interaction
08/31/2006WO2006040481A3 Method for diagnosing and treating crohn's disease
08/31/2006WO2006035418A3 Microcapsules comprising a methylxanthine and a corticosteroid
08/31/2006WO2006035417A3 Dihydropyrimidine microcapsule - formulations
08/31/2006WO2006035244A3 Ecteinascidin compounds as anti -inflammatory agents
08/31/2006WO2006035068A3 Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
08/31/2006WO2006033709A3 Novel nucleoside derivatives
08/31/2006WO2006031610A3 Bicyclic anilide spirolactam cgrp receptor antagonists
08/31/2006WO2006027786A8 Use of liposomal glucocorticoids for treating inflammatory states
08/31/2006WO2006027345A3 Novel 3-thia-10-aza-phenanthrene derivatives
08/31/2006WO2006026368A3 Development of fluorogenic substrates for monoamine oxidases (mao-a and mao-b)
08/31/2006WO2006023852A3 Modulators of muscarinic receptors
08/31/2006WO2006020003A3 Ophthalmic compositions for treating ocular hypertension
08/31/2006WO2006017524A3 Preventing pathological increases in the rate of nerve cell suicide in immature nervous systems
08/31/2006WO2006013193A3 Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors
08/31/2006WO2006010969A8 New heterocyclic carboxylic acid amide derivatives
08/31/2006WO2006010077A3 Prodrugs of lonidamine and lonidamine analogs
08/31/2006WO2006009602A3 Multiple ppi dosage form
08/31/2006WO2006003013B1 NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17β-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1
08/31/2006WO2006000228A3 Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
08/31/2006WO2005115380A3 Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
08/31/2006WO2005111038A3 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
08/31/2006WO2005110391A3 Compounds for treating human papillomavirus
08/31/2006WO2005107792A3 Compositions and methods for treatment of protein misfolding diseases
08/31/2006WO2005092441A3 Extended cycle multiphasic oral contraceptive method
08/31/2006WO2005077968A3 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
08/31/2006WO2005056014A8 Methods for suppressing an immune response or a treating a proliferative disorder
08/31/2006WO2005051318A3 Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
08/31/2006WO2005044273A8 Controlled release delivery system for nasal applications
08/31/2006WO2005041894A3 Compositions and methods for treating, preventing, reversing and inhibiting pain
08/31/2006WO2005039503A3 Prenylation inhibitors reduce host cell permissiveness to viral replication
08/31/2006WO2005035507A3 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
08/31/2006WO2005030118A3 Targeted release of nitric oxide in the cns circulation for modulating the bbb and treating disorders
08/31/2006WO2005015159A3 Methods for modulating a drug-related effect or behavior
08/31/2006WO2004087053A3 Dipeptidyl peptidase inhibitors
08/31/2006US20060194972 Process for the production of imidazopyridin-8-ones
08/31/2006US20060194971 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission
08/31/2006US20060194970 Process for producing imide compound
08/31/2006US20060194968 Cyclic benizimidazoles